Skip to main content
Top
Published in: European Journal of Nutrition 2/2013

01-03-2013 | Original Contribution

Ellagic acid attenuates high-carbohydrate, high-fat diet-induced metabolic syndrome in rats

Authors: Sunil K. Panchal, Leigh Ward, Lindsay Brown

Published in: European Journal of Nutrition | Issue 2/2013

Login to get access

Abstract

Background

Fruits and nuts may prevent or reverse common human health conditions such as obesity, diabetes and hypertension; together, these conditions are referred to as metabolic syndrome, an increasing problem. This study has investigated the responses to ellagic acid, present in many fruits and nuts, in a diet-induced rat model of metabolic syndrome.

Methods

Eight- to nine-week-old male Wistar rats were divided into four groups for 16-week feeding with cornstarch diet (C), cornstarch diet supplemented with ellagic acid (CE), high-carbohydrate, high-fat diet (H) and high-carbohydrate, high-fat diet supplemented with ellagic acid (HE). CE and HE rats were given 0.8 g/kg ellagic acid in food from week 8 to 16 only. At the end of 16 weeks, cardiovascular, hepatic and metabolic parameters along with protein levels of Nrf2, NF-κB and CPT1 in the heart and the liver were characterised.

Results

High-carbohydrate, high-fat diet-fed rats developed cardiovascular remodelling, impaired ventricular function, impaired glucose tolerance, non-alcoholic fatty liver disease with increased protein levels of NF-κB and decreased protein levels of Nrf2 and CPT1 in the heart and the liver. Ellagic acid attenuated these diet-induced symptoms of metabolic syndrome with normalisation of protein levels of Nrf2, NF-κB and CPT1.

Conclusions

Ellagic acid derived from nuts and fruits such as raspberries and pomegranates may provide a useful dietary supplement to decrease the characteristic changes in metabolism and in cardiac and hepatic structure and function induced by a high-carbohydrate, high-fat diet by suppressing oxidative stress and inflammation.
Literature
1.
go back to reference Kotronen A, Yki-Järvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:27–38CrossRef Kotronen A, Yki-Järvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28:27–38CrossRef
2.
go back to reference Almeda-Valdés P, Cuevas-Ramos D, Aguilar-Salinas CA (2009) Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol 8(Suppl 1):S18–S24 Almeda-Valdés P, Cuevas-Ramos D, Aguilar-Salinas CA (2009) Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol 8(Suppl 1):S18–S24
3.
go back to reference Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H et al (2005) The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143:722–728 Hamaguchi M, Kojima T, Takeda N, Nakagawa T, Taniguchi H, Fujii K, Omatsu T, Nakajima T, Sarui H et al (2005) The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143:722–728
4.
go back to reference Qiao Q, Gao W, Zhang L, Nyamdorj R, Tuomilehto J (2007) Metabolic syndrome and cardiovascular disease. Ann Clin Biochem 44:232–263CrossRef Qiao Q, Gao W, Zhang L, Nyamdorj R, Tuomilehto J (2007) Metabolic syndrome and cardiovascular disease. Ann Clin Biochem 44:232–263CrossRef
5.
go back to reference Powell EE, Jonsson JR, Clouston AD (2005) Steatosis: co-factor in other liver diseases. Hepatology 42:5–13CrossRef Powell EE, Jonsson JR, Clouston AD (2005) Steatosis: co-factor in other liver diseases. Hepatology 42:5–13CrossRef
6.
go back to reference Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S (2005) Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42:44–52CrossRef Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S (2005) Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42:44–52CrossRef
7.
go back to reference Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709–2716CrossRef Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709–2716CrossRef
8.
go back to reference Fabbrini E, Sullivan S, Klein S (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51:679–689CrossRef Fabbrini E, Sullivan S, Klein S (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51:679–689CrossRef
9.
go back to reference Adiels M, Taskinen MR, Borén J (2008) Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep 8:60–64CrossRef Adiels M, Taskinen MR, Borén J (2008) Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep 8:60–64CrossRef
10.
go back to reference Lee JM, Johnson JA (2004) An important role of Nrf2-ARE pathway in the cellular defense mechanism. J Biochem Mol Biol 37:139–143CrossRef Lee JM, Johnson JA (2004) An important role of Nrf2-ARE pathway in the cellular defense mechanism. J Biochem Mol Biol 37:139–143CrossRef
11.
go back to reference Li Q, Verma IM (2002) NF-kappaB regulation in the immune system. Nat Rev Immunol 2:725–734CrossRef Li Q, Verma IM (2002) NF-kappaB regulation in the immune system. Nat Rev Immunol 2:725–734CrossRef
12.
go back to reference Sanyal AJ (2001) Insulin resistance and nonalcoholic steatohepatitis: fat or fiction? Am J Gastroenterol 96:274–276CrossRef Sanyal AJ (2001) Insulin resistance and nonalcoholic steatohepatitis: fat or fiction? Am J Gastroenterol 96:274–276CrossRef
13.
go back to reference Pessayre D, Fromenty B (2005) NASH: a mitochondrial disease. J Hepatol 42:928–940CrossRef Pessayre D, Fromenty B (2005) NASH: a mitochondrial disease. J Hepatol 42:928–940CrossRef
14.
go back to reference Narasimhan S, Gokulakrishnan K, Sampathkumar R, Farooq S, Ravikumar R, Mohan V, Balasubramanyam M (2010) Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clin Biochem 43:815–821CrossRef Narasimhan S, Gokulakrishnan K, Sampathkumar R, Farooq S, Ravikumar R, Mohan V, Balasubramanyam M (2010) Oxidative stress is independently associated with non-alcoholic fatty liver disease (NAFLD) in subjects with and without type 2 diabetes. Clin Biochem 43:815–821CrossRef
15.
go back to reference Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499–511CrossRef Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y et al (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499–511CrossRef
16.
go back to reference Libby P (2006) Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 83:456S–460S Libby P (2006) Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 83:456S–460S
17.
go back to reference Dhalla NS, Temsah RM, Netticadan T (2000) Role of oxidative stress in cardiovascular diseases. J Hypertens 18:655–673CrossRef Dhalla NS, Temsah RM, Netticadan T (2000) Role of oxidative stress in cardiovascular diseases. J Hypertens 18:655–673CrossRef
18.
go back to reference Mari Kannan M, Darlin Quine S (2012) Mechanistic clues in the protective effect of ellagic acid against apoptosis and decreased mitochondrial respiratory enzyme activities in myocardial infarcted rats. Cardiovasc Toxicol 12:56–63CrossRef Mari Kannan M, Darlin Quine S (2012) Mechanistic clues in the protective effect of ellagic acid against apoptosis and decreased mitochondrial respiratory enzyme activities in myocardial infarcted rats. Cardiovasc Toxicol 12:56–63CrossRef
19.
go back to reference Talcott ST, Lee JH (2002) Ellagic acid and flavonoid antioxidant content of muscadine wine and juice. J Agric Food Chem 50:3186–3192CrossRef Talcott ST, Lee JH (2002) Ellagic acid and flavonoid antioxidant content of muscadine wine and juice. J Agric Food Chem 50:3186–3192CrossRef
20.
go back to reference Ateşşahín A, Ceríbaşi AO, Yüce A, Bulmus Ö, Cikim G (2007) Role of ellagic acid against cisplatin-induced nephrotoxicity and oxidative stress in rats. Basic Clin Pharmacol Toxicol 100:121–126 Ateşşahín A, Ceríbaşi AO, Yüce A, Bulmus Ö, Cikim G (2007) Role of ellagic acid against cisplatin-induced nephrotoxicity and oxidative stress in rats. Basic Clin Pharmacol Toxicol 100:121–126
21.
go back to reference Türk G, Ateşşahín A, Sönmez M, Ceribaşi AO, Yüce A (2008) Improvement of cisplatin-induced injuries to sperm quality, the oxidant-antioxidant system, and the histologic structure of the rat testis by ellagic acid. Fertil Steril 89:1474–1481CrossRef Türk G, Ateşşahín A, Sönmez M, Ceribaşi AO, Yüce A (2008) Improvement of cisplatin-induced injuries to sperm quality, the oxidant-antioxidant system, and the histologic structure of the rat testis by ellagic acid. Fertil Steril 89:1474–1481CrossRef
22.
go back to reference Yüce A, Ateşşahín A, Ceribaşi AO, Aksakal M (2007) Ellagic acid prevents cisplatin-induced oxidative stress in liver and heart tissue of rats. Basic Clin Pharmacol Toxicol 101:345–349CrossRef Yüce A, Ateşşahín A, Ceribaşi AO, Aksakal M (2007) Ellagic acid prevents cisplatin-induced oxidative stress in liver and heart tissue of rats. Basic Clin Pharmacol Toxicol 101:345–349CrossRef
23.
go back to reference Mari Kannan M, Darlin Quine S (2011) Pharmacodynamics of ellagic acid on cardiac troponin-T, lyosomal enzymes and membrane bound ATPases: mechanistic clues from biochemical, cytokine and in vitro studies. Chem Biol Interact 193:154–161CrossRef Mari Kannan M, Darlin Quine S (2011) Pharmacodynamics of ellagic acid on cardiac troponin-T, lyosomal enzymes and membrane bound ATPases: mechanistic clues from biochemical, cytokine and in vitro studies. Chem Biol Interact 193:154–161CrossRef
24.
go back to reference Mari Kannan M, Darlin Quine S (2011) Ellagic acid ameliorates isoproterenol induced oxidative stress: evidence from electrocardiological, biochemical and histological study. Eur J Pharmacol 659:45–52CrossRef Mari Kannan M, Darlin Quine S (2011) Ellagic acid ameliorates isoproterenol induced oxidative stress: evidence from electrocardiological, biochemical and histological study. Eur J Pharmacol 659:45–52CrossRef
25.
go back to reference Losso JN, Bansode RR, Trappey A 2nd, Bawadi HA, Truax R (2004) In vitro anti-proliferative activities of ellagic acid. J Nutr Biochem 15:672–678CrossRef Losso JN, Bansode RR, Trappey A 2nd, Bawadi HA, Truax R (2004) In vitro anti-proliferative activities of ellagic acid. J Nutr Biochem 15:672–678CrossRef
26.
go back to reference Rosillo MA, Sanchez-Hidalgo M, Cardeno A, de la Lastra CA (2011) Protective effect of ellagic acid, a natural polyphenolic compound, in a murine model of Crohn’s disease. Biochem Pharmacol 82:737–745CrossRef Rosillo MA, Sanchez-Hidalgo M, Cardeno A, de la Lastra CA (2011) Protective effect of ellagic acid, a natural polyphenolic compound, in a murine model of Crohn’s disease. Biochem Pharmacol 82:737–745CrossRef
27.
go back to reference Gümüş M, Yüksel H, Evliyaoğlu O, Kapan M, Böyük A, Önder A, Aldemir M (2011) Effects of ellagic acid on copper, zinc, and biochemical values in serum and liver of experimental cholestatic rats. Biol Trace Elem Res 143:386–393CrossRef Gümüş M, Yüksel H, Evliyaoğlu O, Kapan M, Böyük A, Önder A, Aldemir M (2011) Effects of ellagic acid on copper, zinc, and biochemical values in serum and liver of experimental cholestatic rats. Biol Trace Elem Res 143:386–393CrossRef
28.
go back to reference Hwang JM, Cho JS, Kim TH, Lee YI (2010) Ellagic acid protects hepatocytes from damage by inhibiting mitochondrial production of reactive oxygen species. Biomed Pharmacother 64:264–270CrossRef Hwang JM, Cho JS, Kim TH, Lee YI (2010) Ellagic acid protects hepatocytes from damage by inhibiting mitochondrial production of reactive oxygen species. Biomed Pharmacother 64:264–270CrossRef
29.
go back to reference Girish C, Koner BC, Jayanthi S, Ramachandra Rao K, Rajesh B, Pradhan SC (2009) Hepatoprotective activity of picroliv, curcumin and ellagic acid compared to silymarin on paracetamol induced liver toxicity in mice. Fundam Clin Pharmacol 23:735–745CrossRef Girish C, Koner BC, Jayanthi S, Ramachandra Rao K, Rajesh B, Pradhan SC (2009) Hepatoprotective activity of picroliv, curcumin and ellagic acid compared to silymarin on paracetamol induced liver toxicity in mice. Fundam Clin Pharmacol 23:735–745CrossRef
30.
go back to reference Panchal SK, Brown L (2011) Cardioprotective and hepatoprotective effects of ellagitannins from European oak bark (Quercus petraea L.) extract in rats. Eur J Nutr. doi:101007/s00394-011-0277-1 Panchal SK, Brown L (2011) Cardioprotective and hepatoprotective effects of ellagitannins from European oak bark (Quercus petraea L.) extract in rats. Eur J Nutr. doi:101007/​s00394-011-0277-1
31.
go back to reference Panchal SK, Poudyal H, Iyer A, Nazer R, Alam MA, Diwan V, Kauter K, Sernia C, Campbell F et al (2011) High-carbohydrate, high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats. J Cardiovasc Pharmacol 57:611–624CrossRef Panchal SK, Poudyal H, Iyer A, Nazer R, Alam MA, Diwan V, Kauter K, Sernia C, Campbell F et al (2011) High-carbohydrate, high-fat diet-induced metabolic syndrome and cardiovascular remodeling in rats. J Cardiovasc Pharmacol 57:611–624CrossRef
32.
go back to reference Poudyal H, Campbell F, Brown L (2010) Olive leaf extract attenuates cardiac, hepatic, and metabolic changes in high carbohydrate-, high fat-fed rats. J Nutr 140:946–953CrossRef Poudyal H, Campbell F, Brown L (2010) Olive leaf extract attenuates cardiac, hepatic, and metabolic changes in high carbohydrate-, high fat-fed rats. J Nutr 140:946–953CrossRef
33.
go back to reference Poudyal H, Panchal SK, Waanders J, Ward L, Brown L (2012) Lipid redistribution by alpha-linolenic acid-rich chia seed inhibits stearoyl-CoA desaturase-1 and induces cardiac and hepatic protection in diet-induced obese rats. J Nutr Biochem 23:153–162CrossRef Poudyal H, Panchal SK, Waanders J, Ward L, Brown L (2012) Lipid redistribution by alpha-linolenic acid-rich chia seed inhibits stearoyl-CoA desaturase-1 and induces cardiac and hepatic protection in diet-induced obese rats. J Nutr Biochem 23:153–162CrossRef
34.
go back to reference Ward LC, Battersby KJ (2009) Assessment of body composition of rats by bioimpedance spectroscopy validation against dual-energy X-ray absorptiometry. Scand J Lab Anim Sci 36:253–261 Ward LC, Battersby KJ (2009) Assessment of body composition of rats by bioimpedance spectroscopy validation against dual-energy X-ray absorptiometry. Scand J Lab Anim Sci 36:253–261
35.
go back to reference Poudyal H, Panchal S, Brown L (2010) Comparison of purple carrot juice and beta-carotene in a high-carbohydrate, high-fat diet-fed rat model of the metabolic syndrome. Br J Nutr 104:1322–1332CrossRef Poudyal H, Panchal S, Brown L (2010) Comparison of purple carrot juice and beta-carotene in a high-carbohydrate, high-fat diet-fed rat model of the metabolic syndrome. Br J Nutr 104:1322–1332CrossRef
36.
go back to reference Panchal SK, Poudyal H, Arumugam TV, Brown L (2011) Rutin attenuates metabolic changes, nonalcoholic steatohepatitis, and cardiovascular remodeling in high-carbohydrate, high-fat diet-fed rats. J Nutr 141:1062–1069CrossRef Panchal SK, Poudyal H, Arumugam TV, Brown L (2011) Rutin attenuates metabolic changes, nonalcoholic steatohepatitis, and cardiovascular remodeling in high-carbohydrate, high-fat diet-fed rats. J Nutr 141:1062–1069CrossRef
37.
go back to reference Diwan V, Poudyal H, Brown L (2011) Piperine attenuates cardiovascular, liver and metabolic changes in high carbohydrate, high fat-fed rats. Cell Biochem Biophys. doi:101007/s12013-011-9306-1 Diwan V, Poudyal H, Brown L (2011) Piperine attenuates cardiovascular, liver and metabolic changes in high carbohydrate, high fat-fed rats. Cell Biochem Biophys. doi:101007/​s12013-011-9306-1
38.
go back to reference Tak PP, Firestein GS (2001) NF-κB: a key role in inflammatory diseases. J Clin Invest 107:7–11CrossRef Tak PP, Firestein GS (2001) NF-κB: a key role in inflammatory diseases. J Clin Invest 107:7–11CrossRef
39.
go back to reference Bachmann K, Pardoe D, White D (1996) Scaling basic toxicokinetic parameters from rat to man. Environ Health Perspect 104:400–407CrossRef Bachmann K, Pardoe D, White D (1996) Scaling basic toxicokinetic parameters from rat to man. Environ Health Perspect 104:400–407CrossRef
40.
go back to reference Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22:659–661CrossRef Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22:659–661CrossRef
41.
go back to reference Scalbert A, Williamson G (2000) Dietary intake and bioavailability of polyphenols. J Nutr 130:2073S–2085S Scalbert A, Williamson G (2000) Dietary intake and bioavailability of polyphenols. J Nutr 130:2073S–2085S
Metadata
Title
Ellagic acid attenuates high-carbohydrate, high-fat diet-induced metabolic syndrome in rats
Authors
Sunil K. Panchal
Leigh Ward
Lindsay Brown
Publication date
01-03-2013
Publisher
Springer-Verlag
Published in
European Journal of Nutrition / Issue 2/2013
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI
https://doi.org/10.1007/s00394-012-0358-9

Other articles of this Issue 2/2013

European Journal of Nutrition 2/2013 Go to the issue